Cargando…
Analysis of online user discussions on Reddit associated with the transition of use between HIV PrEP therapy
In 2019, the U.S. Food and Drug Administration (FDA) approved emtricitabine and tenofovir alafenamide (Descovy) as another option for HIV pre-exposure prophylaxis (PrEP) prevention for high-risk adults and adolescents. With the introduction of this new PrEP, millions of current users on emtricitabin...
Autores principales: | Godinez, Hector, Xu, Qing, McMann, Tiana J., Li, Jiawei, Mackey, Timothy Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338828/ https://www.ncbi.nlm.nih.gov/pubmed/37457283 http://dx.doi.org/10.3389/fpubh.2023.1073813 |
Ejemplares similares
-
Predictors of PrEP awareness, PrEP discussion and interest in long‐acting injectable PrEP among Filipina transfeminine adults
por: Restar, Arjee Javellana, et al.
Publicado: (2023) -
Complex PrEP: the factors requiring consultant-led review of PrEP users
por: Tittle, Victoria, et al.
Publicado: (2022) -
Interest in Switching to On-Demand HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Users of Daily PrEP: An Online Survey
por: Cornelisse, Vincent J, et al.
Publicado: (2019) -
PrEP stigma among current and non-current PrEP users in Thailand: A comparison between hospital and key population-led health service settings
por: Chautrakarn, Sineenart, et al.
Publicado: (2022) -
Knowledge and barriers of PrEP delivery among diverse groups of potential PrEP users in Central Uganda
por: Muwonge, Timothy R., et al.
Publicado: (2020)